(Q73503617)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

title

Does prolonged combined androgen blockade have survival benefits over short-term combined androgen blockade therapy? (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

author name string

M F Sarosdy

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

P F Schellhammer

2

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

R Johnson

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

K Carroll

4

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

G J Kolvenbag

5

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

language of work or name

English

0 references

publication date

1 March 2000

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

volume

55

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

issue

3

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

page(s)

391-5; discussion 395-6

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

Levels of plasma steroid glucuronides in intact and castrated men with prostatic cancer

4 November 2019

cites work

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

New hormonal therapy in prostate cancer: combined use of a pure antiandrogen and an LHRH agonist.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Simultaneous administration of pure antiandrogens, a combination necessary for the use of luteinizing hormone-releasing hormone agonists in the treatment of prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

A controlled trial of leuprolide with and without flutamide in prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

A multicenter randomized trial comparing the luteinizing hormone-releasing hormone analogue goserelin acetate alone and with flutamide in the treatment of advanced prostate cancer. The International Prostate Cancer Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Goserelin acetate with or without flutamide in the treatment of patients with locally advanced or metastatic prostate cancer. The Italian Prostatic Cancer Project (PONCAP) Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Zoladex vs. Zoladex plus cyproterone acetate in the treatment of advanced prostatic cancer: a multicenter Italian study

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Maximal androgen blockade: final analysis of EORTC phase III trial 30853. EORTC Genito-Urinary Tract Cancer Cooperative Group and the EORTC Data Center

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Maximum androgen blockade using LHRH agonist buserelin in combination with short-term (two weeks) or long-term (continuous) cyproterone acetate is not superior to standard androgen deprivation in the treatment of advanced prostate cancer. Final anal

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

A phase III trial of zoladex and flutamide versus orchiectomy in the treatment of patients with advanced carcinoma of the prostate

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Bilateral orchiectomy with or without flutamide for metastatic prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Long-term efficacy and safety of nilutamide plus castration in advanced prostate cancer, and the significance of early prostate specific antigen normalization. International Anandron Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

A further analysis of European Organization for Research and Treatment of Cancer protocol 30805. Orchidectomy versus orchidectomy plus cyproterone acetate versus low-dose diethylstilbestrol

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Bilateral orchidectomy and flutamide versus orchidectomy alone in newly diagnosed patients with metastatic carcinoma of the prostate--an Australian multicentre trial

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

A controlled trial of castration with and without nilutamide in metastatic prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

A randomized double-blind study evaluating Anandron associated with orchiectomy in stage D prostate cancer

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Maximum androgen-blockade with medical or surgical castration in advanced prostate cancer: A meta-analysis of nine published randomized controlled trials and 4128 patients using flutamide.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Comparison of LHRH Analogue (Zoladex) with Orchiectomy in Patients with Metastatic Prostatic Carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Goserelin versus orchiectomy in the treatment of advanced prostate cancer: final results of a randomized trial. Zoladex Prostate Study Group.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Clinical benefits of bicalutamide compared with flutamide in combined androgen blockade for patients with advanced prostatic carcinoma: final report of a double-blind, randomized, multicenter trial. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

A controlled trial of bicalutamide versus flutamide, each in combination with luteinizing hormone-releasing hormone analogue therapy, in patients with advanced prostate cancer. Casodex Combination Study Group

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Flutamide Eliminates the Risk of Disease Flare in Prostatic Cancer Patients Treated with a Luteinizing Hormone-Releasing Hormone Agonist

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Prevention of the Transient Adverse Effects of a Gonadotropin-Releasing Hormone Analogue (Buserelin) in Metastatic Prostatic Carcinoma by Administration of an Antiandrogen (Nilutamide)

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Is disease flare a problem?

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Sudden death due to disease flare with luteinizing hormone-releasing hormone agonist therapy for carcinoma of the prostate.

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma

1 reference

https://api.crossref.org/works/10.1016%2FS0090-4295%2899%2900574-9

7 January 2021

10.1016/S0090-4295(99)00574-9

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:10699617%20AND%20SRC:MED&resulttype=core&format=json

4 November 2019

1 reference